Short course treatment regimens for multiple drug resistant tuberculosis in Arkhangelsk, Murmansk and Belgorod Regions

In 2016, World Health Organization published new guidelines for the treatment of multiple drug resistant tuberculosis (MDR TB), which stated that minimum duration of treatment was 9 months. In the Russian Federation, it is impossible to use short course 9-month treatment for MDR-TB since clofazimine is not registered in this country.

The objective of the study: to compare efficacy of short course 9-month treatment of MDR-TB and the standard treatment regimen lasting 18-24 months recommended by the Russian Society of Phthisiologists (ROF).

Subjects and methods. 180 MDR TB cases notified in 2015, and 179 MDR TB cases notified in 2016 were enrolled into the trial and treated for 18-24 and 12 months. respectively. Chemotherapy regimens included anti-tuberculosis drugs recommended by the ROF. With a 12-month course of treatment, an injectable drug was used for 4 months and discontinued after culture conversion.

1. Gayda А.I., Nikishova E.I., Maryandyshev А.O. Postponed treatment outcomes of patients with multiple drug resistant tuberculosis who interrupted the course of treatment. Tuberculosis and Lung Diseases, 2014, no. 12, pp. 47-54. (In Russ.)

2. Federalnye klinicheskiye rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya s mnozhestvennoy i shirokoy lekarstennoy ustoichivostyu vozbuditelya, tretye izdaniye. [Federal clinical recommendations for diagnosis and treatment of respiratory tuberculosis with multiple and extensive drug resistance. 3rd Edition]. Rossiyskoe Obschestvo Ftiziatrov Publ., 68 p.

3. Epidemicheskaya situatsiya po tuberkulezu v Rossiyskoy Federatsii v 2017 g. [Epidemic tuberculosis situation in the Russian Federation in 2017]. Federalny Tsentr Monitoringa Protivodeystviya Rasprostraneniyu Tuberkuleza v RF Publ., (Epub.), Moscow, Available: https://www.medunet.ru/informatizatsiya/tsentr-monitoringa-tuberkuleza#h2-poslednie-dannye.

4. Aung K.J.M., Van Deun A., Declercq E. et al. Successful “9-month Bangladesh regimen” for multidrug resistant tuberculosis among over 500 consecutive patients. Int. J. Tub. Lung Dis., 2014, no. 18, pp. 1188-1194.

5. Balabanova Y., Fiebig L., Ignatyeva O. et al. Multidrug-resistant TB in Eastern region of the EU: is the shorter regimen an exception or a rule? Thorax, 2017, vol. 72, pp. 850-852.

6. Global tuberculosis report 2018, Geneva: World Health Organization, 2018; 277.

7. Kuaban C. et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int. J. Tub. Lung Dis., vol. 19, no. 5, pp. 517-524.

8. Nunn A.J., Rusen I.D., Van Deun A., Torrea G., Phillips P.P., Chiang C.Y., Squire S.B., Madan J., Meredith S.K. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials, 2014, vol. 15, pp. 353.

9. Piubello A., Harouna S.H., Souleymane M.B., Boukary I., Morou S., Daouda M., Hanki Y., Van Deun A. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int. J. Tub. Lung Dis., 2014, vol. 18, no. 10, pp. 1188-1194.

10. Riya Moodley, Thomas R. Godec on behalf of the STREAM Trial Team. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur. Respir. Review, 2016, vol. 25, pp. 29-35.

11. Van Deun A., Kya Jai Maug A., Halim M.A., Kumar Das P., RanjanSarker M., Daru P. et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med., 2010, vol. 182, pp. 684-692.